Suchergebnisse - "Harter, Philipp"

PubPharm (20)

1

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc) : a randomised, open-label, phase 3 trial

enthalten in: Lancet (London, England) | 2024

von Oaknin, A. | Gladieff, L. | Martínez-García, J. | +117

2

AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer : a multicenter randomized phase III trial

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2023

von Heitz, F. | Marth, C. | Henry, S. | +15

3

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer : AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Pfisterer, J. | Joly, F. | Kristensen, G. | +27

CommentIn: J Clin Oncol. 2023 Apr 1;41(10):1952-1953. - PMID 36763910

4

Perception of side effects associated with anticancer treatment in women with breast or ovarian cancer (KEM-GO-1) : a prospective trial

enthalten in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer | 2020

von Ataseven, B. | Frindte, J. | Harter, P. | +13

5

Bevacizumab and platinum-based combinations for recurrent ovarian cancer : a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2020

von Pfisterer, J. | Shannon, C. | Baumann, K. | +129

CommentIn: Lancet Oncol. 2020 May;21(5):614-615. - PMID 32305100

6

Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

enthalten in: International journal of cancer | 2020

von Ray-Coquard, I. | Cibula, D. | Mirza, M. | +22

7

Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years

enthalten in: Gynecologic oncology | 2019

von Heilmann, T. | Pfisterer, J. | Hempel, A. | +6

8

Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer

enthalten in: Gynecologic oncology | 2017

von Heitz, F. | Hengsbach, A. | Harter, P. | +7

9

Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7)

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2016

von Harter, P. | Sehouli, J. | Reuss, A. | +13

10

Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase

enthalten in: Gynecologic oncology | 2016

von Grabowski, J. | Harter, P. | Heitz, F. | +8